Bluejay Announces Receipt of PRIME Designation from European Medicines Agency (EMA) for BJT-778 for the Treatment of Chronic Hepatitis Delta Virus Infection - 3/25/2024
Global Clinical Trial Investigates Novel Heart Failure Treatment
VCs take significant but careful risks in funding novel efforts to address unmet medical needs, as RiverVest portfolio company Alleviant Medical aims to do for large underserved subsets of heart failure patients. Read RiverVest’s latest Expert Insight to learn why we chose to invest in Alleviant and its novel, no-implant shunt therapy.
ST. LOUIS, December 14, 2023 – RiverVest Venture Partners today announced the promotions of three current team members: Karen Spilizewski and Izaac Zike, Ph.D. to Managing Director and Pascal Krotee, Ph.D. to Principal.
Good Therapeutics, founded in 2016 by John Mulligan, Ph.D., was acquired by Roche in 2022 for $250 million upfront plus potential milestone payments. Even better, Mulligan and company retained its platform and the ability to mine it for innovative drugs to fight cancer and other diseases.
RiverVest strives to improve the lives of patients, support entrepreneurs, and earn the trust of investors through science, strategy, and innovation.Contact us at info@rivervest.com
Transparency in Coverage Rule: To access the machine-readable files created and published by United Healthcare, please click here.